The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 05, 2017

Filed:

Dec. 22, 2014
Applicants:

Development Center for Biotechnology, New Taipei, TW;

National Health Research Institutes, Miaoli County, TW;

Inventors:

Shih-Chong Tsai, New Taipei, TW;

Mingl Chang, New Taipei, TW;

Ta-Tung Yuan, New Taipei, TW;

Shih-Chi Tseng, New Taipei, TW;

Shyi-Jou Chen, New Taipei, TW;

Wei-Tso Chia, New Taipei, TW;

Hsin-Yun Wang, New Taipei, TW;

Neng-Yao Shih, Miaoli County, TW;

Ko-Jiunn Liu, Miaoli County, TW;

Li-Tzong Chen, Miaoli County, TW;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/39 (2006.01); B63B 15/02 (2006.01); A61K 39/395 (2006.01); C07K 16/40 (2006.01); B63B 1/12 (2006.01); B63H 9/08 (2006.01); B63B 15/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 39/3955 (2013.01); B63B 1/121 (2013.01); B63B 15/02 (2013.01); B63H 9/08 (2013.01); C07K 16/40 (2013.01); A61K 2039/505 (2013.01); B63B 2001/123 (2013.01); B63B 2015/005 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against ENO1. The antagonist binds ENO1 and inhibits ENO1 plasminogen receptor activity. The antagonist may be an anti-human ENO1 antibody, or an scFv, Fab, or F(ab)fragment thereof, that specifically binds to human ENO1 (GenBank: AAH50642.1) for the treatment of an inflammatory disease or an immune disorder, which may be multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, systemic Lupus erythematosus, chronic obstructive pulmonary disease (COPD), asthma, allergy, psoriasis, type 1 diabetes mellitus, artherosclerosis or osteoporosis.


Find Patent Forward Citations

Loading…